Nestle to Buy Allergy Treatment Developer for $2.6 Billion

(Bloomberg) -- Nestle SA agreed to buy Aimmune Therapeutics Inc. in a $2.6 billion deal, adding a leader in the treatment of peanut allergies as demand for mainstream consumer goods eases.